We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,121

Patent utility update in Canada clarity may not be explicitly promised
  • SIM. IP Practice
  • Canada
  • June 4 2015

In the past five years, the Canadian Federal Court has invalidated several patents based on an arguably “technical” deficiency the


Federal Court of Appeal affirms rejection of heightened sound prediction patent disclosure requirements
  • Norton Rose Fulbright Canada LLP
  • Canada
  • June 12 2015

Allergan obtained a prohibition order against Apotex under section 6 of the PMNOC Regulations with respect to the drug bimatoprost


The Supreme Court refuses to grant leave to hear “promise of the patent” appeals
  • Bereskin & Parr LLP
  • Canada
  • April 27 2015

On April 23, 2015, the Supreme Court of Canada denied leave to hear an appeal from the Federal Court of Appeal decision in Apotex Inc v Pfizer Canada


Is the Competition Bureau targeting you? New IP enforcement guidelines
  • Bennett Jones LLP
  • Canada
  • June 12 2015

On June 9, 2015, the Canadian Competition Bureau released updated draft Intellectual Property Enforcement Guidelines (IPEGs) for public comment. The


PM(NOC) proceedings: Federal Court of Appeal affirms stringent product specificity requirements for listing patents in Canada
  • McCarthy Tétrault LLP
  • Canada
  • May 6 2015

The Federal Court of Appeal has affirmed the stringent product specificity requirements for listing a patent against a drug for purposes of the


Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights
  • Fasken Martineau DuMoulin LLP
  • Canada
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer


Formulation patent allegations of non-infringement, obviousness and lack of utility justified
  • Borden Ladner Gervais LLP
  • Canada
  • March 2 2015

Servier sought a prohibition order against Apotex in relation to its DIAMICRON MR gliclazide product. The application was dismissed. The patent at


Federal Court of Appeal clarifies misunderstanding: factual basis and line of reasoning need not be disclosed in the patent
  • McCarthy Tétrault LLP
  • Canada
  • June 8 2015

In a decision released on June 3, 2015 (2015 FCA 137), a unanimous Federal Court of Appeal (“FCA”) dismissed Apotex’s appeal of Justice O’Reilly’s


When is a little knowledge a dangerous thing? When it is used to disqualify in-house counsel
  • McCarthy Tétrault LLP
  • Canada
  • February 28 2014

A powerful tool in the litigation arsenal is the bringing of a motion to remove counsel from a file, either because she possesses disqualifying


Federal Court dismisses application for a prohibition order in respect of PATADAY eye drop solution
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 18 2014

This case concerns a proposed generic version of the brand name drug PATADAY, an eye drop solution used to treat allergic and inflammatory eye